Lucas Moreno: The first publication from the BEACON-Neuroblastoma trial is now live in the Journal of Clinical Oncology
Lucas Moreno, Division Head of Paediatric Oncology and Haematology at Vall d’Hebron Barcelona Hospital Campus, shared a post on LinkedIn:
“I am very pleased to share that the first publication from the BEACON-Neuroblastoma trial is now live in the Journal of Clinical Oncology.
Enormous thanks to the SIOPEN and ITCC communities that made this trial possible; and to all the patients and families that participated.
The trial helped us to identify the combination of bevacizumab, irinotecan and temozolomide as a new option to treat children with relapsed and refractory neuroblastoma. This combination will also be further developed in the subsequent BEACON2 clinical trial that is in set up.
Also, thanks to BBC News for echoing this trial and the major unmet need to have new treatment options within early phase clinical trials for children and families with relapsed and refractory neuroblastoma.
The trial was supported by Cancer Research UK (grant CRUK/11/056) and Imagine for Margo. Funding for national coordinating centers was also received from the Danish Childhood Cancer Foundation (grants no. 2015-13 and 2016-0318), the German Children’s Cancer Foundation (DKS 2013.24), 111 des Arts, Enfance & cancer, Enfants Cancer Santé, Kom op tegen Kanker and Zoe for Life.”
Source: Lucas Moreno/LinkedIn